Patient-centric treatment of type 2 diabetes – where and how does semaglutide fit?

Novo Nordisk A/S |

Chair: Alice Cheng (CAN)

18:45 – 18:48Welcome and introductionAlice Cheng (CAN)
18:48 – 19:01Early control mattersKamlesh Khunti (UK)
19:01 – 19:14A patient centered approach with semaglutide John Wilding (UK)
19:14 – 19:27Treatment of ASCVD in T2DKim Conelly (CAN)
19:27 – 19:40Managing T2D later in the disease journeyFilip Knop (DNK)
19:40 – 19:53Time to focus on optimal utilization of GLP-1 RAs in clinical practiceTina Vilsbøll (DNK)
19:53 – 20:13Panel Discussion and Q&AAll speakers
20:13 – 20:15Closing remarksAlice Cheng (CAN)